HU218146B - Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina - Google Patents

Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina Download PDF

Info

Publication number
HU218146B
HU218146B HU9201966A HU196692A HU218146B HU 218146 B HU218146 B HU 218146B HU 9201966 A HU9201966 A HU 9201966A HU 196692 A HU196692 A HU 196692A HU 218146 B HU218146 B HU 218146B
Authority
HU
Hungary
Prior art keywords
polysaccharide
gbmp
group
conjugate
modified
Prior art date
Application number
HU9201966A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT64480A (en
Inventor
Harold J. Jennings
Francis Michon
Original Assignee
National Research Council Of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Of Canada filed Critical National Research Council Of Canada
Publication of HUT64480A publication Critical patent/HUT64480A/hu
Publication of HU218146B publication Critical patent/HU218146B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HU9201966A 1989-12-14 1990-12-13 Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina HU218146B (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
PCT/CA1990/000437 WO1991008772A1 (en) 1989-12-14 1990-12-13 Improved meningococcal polysaccharide conjugate vaccine

Publications (2)

Publication Number Publication Date
HUT64480A HUT64480A (en) 1994-01-28
HU218146B true HU218146B (hu) 2000-06-28

Family

ID=23779371

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9201966A HU218146B (hu) 1989-12-14 1990-12-13 Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina
HU9201966A HU9201966D0 (en) 1989-12-14 1990-12-13 An improved vaccine of meningococcus-polysaccharide conjunction

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU9201966A HU9201966D0 (en) 1989-12-14 1990-12-13 An improved vaccine of meningococcus-polysaccharide conjunction

Country Status (30)

Country Link
US (3) US5576002A (enExample)
EP (1) EP0504202B1 (enExample)
JP (1) JP2637845B2 (enExample)
KR (1) KR0158436B1 (enExample)
CN (4) CN1049223C (enExample)
AR (1) AR243934A1 (enExample)
AT (1) ATE121947T1 (enExample)
AU (1) AU641715B2 (enExample)
BR (1) BR9007917A (enExample)
CA (1) CA2071811C (enExample)
CZ (1) CZ283530B6 (enExample)
DE (1) DE69019164T2 (enExample)
DK (1) DK0504202T3 (enExample)
ES (1) ES2071288T3 (enExample)
FI (2) FI104539B (enExample)
HR (1) HRP920872A2 (enExample)
HU (2) HU218146B (enExample)
IE (1) IE68414B1 (enExample)
IL (1) IL96676A (enExample)
IN (1) IN171747B (enExample)
NO (2) NO305275B1 (enExample)
NZ (1) NZ236471A (enExample)
PH (1) PH30305A (enExample)
PL (2) PL166659B1 (enExample)
RO (1) RO111416B1 (enExample)
RU (1) RU2105568C1 (enExample)
SI (1) SI20008B (enExample)
WO (1) WO1991008772A1 (enExample)
YU (1) YU24391A (enExample)
ZA (1) ZA9010065B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
DK0504202T3 (da) * 1989-12-14 1995-10-02 Ca Nat Research Council Forbedret meningokok-polysaccharid-konjugat vaccine
DK0667787T3 (da) * 1992-09-24 2001-10-29 Ca Nat Research Council Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
TR199701547T1 (xx) * 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
DK1007546T3 (da) 1997-08-27 2009-03-16 Novartis Vaccines & Diagnostic Molekylære mimetika af meningokok-B-epitoper
CZ302615B6 (cs) 1997-12-23 2011-08-03 Baxter Healthcare S.A. Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid
CA2340692A1 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
ATE455793T1 (de) 2001-04-17 2010-02-15 Novartis Vaccines & Diagnostic Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ATE419278T1 (de) * 2002-03-26 2009-01-15 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
ATE513560T1 (de) * 2002-05-14 2011-07-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
RU2359696C2 (ru) * 2002-08-02 2009-06-27 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
JP2006522135A (ja) * 2003-03-31 2006-09-28 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 喘息およびアレルギーの処置のための両性イオン免疫調節剤
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
RU2404995C2 (ru) 2004-06-23 2010-11-27 Чилдрен'С Хоспитал Энд Рисерч Сентер Эт Окленд Производные полисахаридов и их применение для индуцирования иммунной реакции
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2611964C (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
WO2010083477A2 (en) 2009-01-16 2010-07-22 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
DK0504202T3 (da) * 1989-12-14 1995-10-02 Ca Nat Research Council Forbedret meningokok-polysaccharid-konjugat vaccine

Also Published As

Publication number Publication date
KR0158436B1 (ko) 1998-12-01
ES2071288T3 (es) 1995-06-16
IE68414B1 (en) 1996-06-12
CA2071811A1 (en) 1991-06-15
NO973311L (no) 1992-08-14
IN171747B (enExample) 1992-12-26
JPH05505392A (ja) 1993-08-12
NO922316D0 (no) 1992-06-12
FI19991917A7 (fi) 1999-09-09
FI19991917L (fi) 1999-09-09
DK0504202T3 (da) 1995-10-02
DE69019164T2 (de) 1995-09-07
RO111416B1 (ro) 1996-10-31
CN1096516A (zh) 1994-12-21
YU24391A (sh) 1995-12-04
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
WO1991008772A1 (en) 1991-06-27
NO922316L (no) 1992-08-14
RU2105568C1 (ru) 1998-02-27
HRP920872A2 (en) 1997-06-30
CN1100656A (zh) 1995-03-29
AR243934A1 (es) 1993-09-30
CN1049223C (zh) 2000-02-09
AU641715B2 (en) 1993-09-30
PL166035B1 (pl) 1995-03-31
PL166659B1 (pl) 1995-06-30
US5902586A (en) 1999-05-11
IE904513A1 (en) 1991-06-19
CN1055541A (zh) 1991-10-23
EP0504202B1 (en) 1995-05-03
NO305275B1 (no) 1999-05-03
ZA9010065B (en) 1992-02-26
AU6898791A (en) 1991-07-18
CA2071811C (en) 2003-11-04
PH30305A (en) 1997-02-20
HU9201966D0 (en) 1992-10-28
NZ236471A (en) 1992-10-28
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
US5683699A (en) 1997-11-04
IL96676A0 (en) 1991-09-16
FI104539B (fi) 2000-02-29
BR9007917A (pt) 1992-10-20
CZ628490A3 (en) 1997-12-17
NO307835B1 (no) 2000-06-05
ATE121947T1 (de) 1995-05-15
FI922737A0 (fi) 1992-06-12
EP0504202A1 (en) 1992-09-23
CN1100428A (zh) 1995-03-22
JP2637845B2 (ja) 1997-08-06
CN1072506C (zh) 2001-10-10
DE69019164D1 (de) 1995-06-08
CZ283530B6 (cs) 1998-04-15
US5576002A (en) 1996-11-19
SI20008A (sl) 2000-02-29
IL96676A (en) 1996-09-12
CN1036522C (zh) 1997-11-26
PL288271A1 (en) 1991-12-16

Similar Documents

Publication Publication Date Title
HU218146B (hu) Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina
CA2223567C (en) Modified meningococcal polysaccharide conjugate vaccines
US7595307B2 (en) Polysaccharide derivatives and uses in induction of an immune response